105 results about "Malarial parasite" patented technology

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The invention belongs to the technical field of biomedicine, and particularly relates to application of Ackermania muciniphila in improvement and treatment of cerebral malaria caused by Plasmodium berghei. The invention tries to evaluate the effect of the AKK bacterium on improving and treating the cerebral malaria of a mouse under the condition that the AKK bacterium or auxiliary medicines (dihydroartemisinin, rapamycin and atorvastatin) are independently used on a cerebral malaria model of the mouse. Results indicate that the strain can effectively improve behavioristics of mice and immune pathological injuries of all organs, reduce protozoemia and prolong the lifetime of the mice whether the strain is independently used or combined with the drugs, and compared with the strain which is independently used with the drugs, the strain can effectively treat cerebral malaria of the mice. As ackermania muciniphila is common probiotics in human intestinal tracts, the three drugs (dihydroartemisinin, rapamycin and atorvastatin) used in the invention are all clinically used drugs, and if the drugs are clinically transformed to treat human brain malaria caused by plasmodium falciparum, the feasibility is high, and meanwhile, the transformation time can be shortened. According to the invention, a bacterium-medicine synergistic concept is provided for the first time, that is, probiotics can assist medicines in treating diseases, and a solution is provided for treating human cerebral malaria under the guidance of the concept.

Methods of treating malaria comprising administration of compounds of Formula (I′) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The invention relates to application of a mir-331-3p inhibitor in preparation of a medicine for inhibiting malaria mosquito transmission, and belongs to the technical field of biological medicine. Aiming at the technical problems that the existing anti-malarial drug mainly acts on the later stage of plasmodium development and is lack of an effective propagation blocker, the invention provides the miR-331-3p inhibitor which is used for blocking the formation of plasmodium oocysts by inhibiting the interaction between microRNA and a mosquito target gene spetzle. Experiments show that the inhibitor can reduce the mosquito infection rate by about 50%, and has the characteristics of high targeting property, simplicity in operation and the like. The invention provides a novel drug development target for blocking malaria transmission, can effectively supplement the prevention and control blind area of the existing anti-malarial drug, and has important application value in the field of mosquito-borne infectious disease control.

The present invention belongs to the field of biomedical technology and specifically relates to the use of Akkermansia muciniphila in ameliorating and treating cerebral malaria caused by Plasmodium berghei. This study evaluated the efficacy of Akkermansia muciniphila alone or in combination with adjuvant drugs (dihydroartemisinin, rapamycin, and atorvastatin) in ameliorating and treating cerebral malaria in a mouse cerebral malaria model. The results suggest that the bacteria, whether used alone or in combination with other drugs, effectively improved mouse behavior, immune pathological damage to various organs, reduced parasitemia, and prolonged mouse survival, demonstrating its effectiveness in treating cerebral malaria in mice compared to using the drugs alone. Because Akkermansia muciniphila is a common probiotic in the human gut, the three drugs used in this study (dihydroartemisinin, rapamycin, and atorvastatin) are all currently in clinical use. Clinical translation for the treatment of human cerebral malaria caused by Plasmodium falciparum is highly feasible and can also shorten the conversion time. This study proposes for the first time the concept of bacterial-drug synergy, whereby probiotics can complement drug treatments, and provides a solution for the treatment of human cerebral malaria based on this concept.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivery of malaria protein antigens. The present disclosure provides, among other things, polyribonucleotides encoding malaria protein antigens.

According to the purposes of the present disclosure, as embodied and broadly described herein, the present disclosure relates, in one aspect, to scaffold molecules that exhibit potent anti-malarial activity against a variety of Plasmodium strains at different stages of a parasite, such as the red and infrared stages, and pharmaceutical compositions comprising the scaffold molecules. In one aspect, these compounds are tetrahydroacridones having Structure I described herein. In another aspect, the compounds described herein may be used to treat or prevent malaria in a subject.

Disclosed are methods of treating malaria with tetrahydrobenzonaphtyridine carboxanilide (TBN) derivatives and related pyrrolinones and hydrolysis products thereof. These compounds are active against Plasmodium falciparum strains that are resistant to multiple drugs currently on the market. The present invention further relates to novel compounds and pharmaceutical compositions comprising such compounds.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The application discloses a kit for rapidly identifying malignant plasmodium based on an RPA-CRISPR / Cas12a fluorescence system and belongs to the field of detection and testing. The kit comprises a malignant plasmodium RPA specific primer pair, a crRNA fragment, a fluorescence reporter probe, and a buffer and Cas12a protein for a CRISPR reaction. The application is based on RPA technology, CRISPR / Cas12a technology and fluorescence detection technology, and a kit and a detection method for rapidly, accurately, simply and specifically detecting and identifying malignant plasmodium are constructed. The kit and the detection method can be used for detecting malignant plasmodium in a wild or clinical environment, especially in a country with limited resources, and the detection method does not require expensive instruments and equipment and a professional standard laboratory, and therefore has important significance for malaria monitoring, diagnosis and prevention and control.

The present application relates to Compounds of Formula (I) and pharmaceutically acceptable salts or stereoisomers thereof, pharmaceutical compositions thereof, and their use in the treatment and prophylaxis of systemic infections, such as the treatment and prophylaxis of parasitic protozoal Infection, such as malaria, in particular infection by Plasmodium falciparum.

The invention relates to a composition comprising a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID) NO: 1, or a sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to SEQ ID NO: 1 (R21), wherein said polypeptide is in the form of a virus-like particle (VLP), wherein said particle comprises less than 10% free hepatitis B surface antigen protein, for use in the immunisation of a human subject susceptible to Plasmodium falciparum infection, characterised in that said composition is administered in a dosage regimen of at least one dose of 1 μg to 20 μg R21 per administration for a subject at least 18 years old, or at least one dose of 0.5 μg to 10 μg R21 per administration for a subject less than 18 years old. The invention also relates to kits, methods and uses.

The present invention belongs to the field of biomedical technology, and specifically relates to an application of DHA@ZIF-8 in treating mouse cerebral malaria. The present invention first establishes a mouse cerebral malaria model, then uses ZIF-8@DHA on the model for treatment, and observes the therapeutic effect of the nano drug on mouse cerebral malaria by behavioral, pathological, molecular biological and other technical means; the present invention uses ZIF-8 as a carrier to achieve the effect of sustained release of the drug, thereby extending its action time in the body to more effectively kill malarial parasites. Compared with natural administration, the action time of DHA is extended.

This invention provides the application of Pulsatilla saponin B4 in the preparation of antimalarial drugs, which can significantly improve weight loss, peripheral blood parasitemia, and survival rate in mice infected with lethal Plasmodium. Its mechanism of action is not to directly kill Plasmodium, but to regulate the host immune system, including activating T / B cell immune responses, upregulating pro-inflammatory factors and interferon signaling pathways, and downregulating Arg1 expression. At the same time, Pulsatilla saponin B4 can alleviate immunopathological damage to organs such as the spleen and liver, restore the homeostasis of the spleen's immune microenvironment, and protect the normal structure of tissues. As a natural product, this compound has the characteristics of multiple targets and low toxicity, and has the dual advantages of anti-infection and immune homeostasis regulation, showing good prospects for clinical application and translation.

In one aspect, the present invention relates to compounds that inhibit asexual erythroid parasites (PfABS) of Plasmodium falciparum. In one aspect, these compounds exhibit sub-mmol potency against the erythroid phase of Plasmodium falciparum and other Plasmodium. In another aspect, these compounds are soluble in aqueous solutions at pH 7.4, making them suitable for oral administration by patients. Also disclosed are methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of treating or preventing malaria using the compounds. This abstract is intended as a scanning tool for a field-specific search and is not intended to be limiting of the present disclosure.

The present disclosure provides an isolated strain of Amycolatopsis sp. WGS_07 having accession number MCC 0218. The present disclosure provides a process for synthesizing furano-naphthoquinone and pyrazinone derivatives using a novel strain Amycolatopsis sp. . The novel compounds synthesized possesses activity against gram positive bacteria, malarial parasites, and various cancers.

The present disclosure relates to a pharmaceutical composition to combat artemisinin resistance in malaria with the identification of Plasmodium falciparum (Pf) glutamine synthetase (GS) as a drug tar

Disclosed herein are methods and compositions for treating and / or preventing Plasmodium falciparum malaria by administering a compound that mimics the binding of anti-Plasmodium falciparum Glutamic Acid Rich Protein (PfGARP).

In a method for diagnosing dengue fever and malaria, DNA extracted from a sample is added to a composition including a first primer set of nucleotide sequences of SEQ ID Nos. 1 to 6 and a second primer set of nucleotide sequences of SEQ ID Nos. 7 to 11, a loop-mediated isothermal amplification (LAMP) reaction of the DNA is performed to produce a colorimetric change, an image of the reaction tube is captured, the image is analyzed using a trained artificial intelligence model to determine whether the reaction indicates a positive or negative result for Dengue virus or Plasmodium falciparum.

The present invention discloses a malaria blood smear cell detection and segmentation method based on Mask R-CNN, which realizes the detection and segmentation of malarial parasites and red blood cells in thin blood smear images, including: using VoVNet-57 as the backbone feature extraction network to extract richer thin blood smear image features; improving the feature pyramid network structure to make full use of the cell classification information rich in high-level features to enhance the representation ability of the underlying features; using the attenuation function to improve the traditional non-maximum suppression algorithm to reduce the cases of missed detection due to cell stacking; reconstructing the cell classification loss function to improve the problem of low detection accuracy due to imbalanced cell categories. The method proposed in the present invention can effectively improve the accuracy of the Mask R-CNN network model for cell detection and segmentation in thin blood smear images, providing a scientific basis for malaria diagnosis.

An immunogen generally includes an immunogenic carrier that includes a virus-like particle (VLP) and an antigenic Anopheles spp. TRIO peptide that includes amino acids VDDLMAKFN (SEQ ID NO:1) or AANLRDKFN (SEQ ID NO:5) linked to the immunogenic carrier. The immunogen can be formulated into a composition such as vaccine. The composition or vaccine may be used to treat a subject having, or at risk of having malaria. The composition or vaccine may be used to treat a subject having Plasmodium falciparum blood stage parasitemia.

The present invention relates to a vaccine composition for preventing malaria, comprising, as an active ingredient, an elongation factor-2 (EF-2) recombinant protein derived from Plasmodium falciparum and, more specifically, to a vaccine composition for preventing malaria, comprising, as an active ingredient, EF-2 recombinant peptides derived from Plasmodium falciparum consisting of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and use thereof.

The present invention provides an antimalarial composition comprising arjunetin and artemisinin. The composition exhibits synergistic antimalarial effect against malaria causing Plasmodium species including Plamsodium falciparum, P berghe species. The composition comprising Arjunetin and Artemisinin demonstrated potent antimalarial activity in vivo and in vitro with better survival and low parasite burden in the blood.

Among the various aspects of the present disclosure is the provision of methods of suppressing Plasmodium parasite growth or infectivity or treating malaria comprising administering a polybasic antimalarial agent. The polybasic peptides and polymers provided can be used for the treatment of Plasmodium falciparum and other plasmodium species that cause human malaria.

The invention belongs to the technical field of biological detection, and particularly relates to a hybridoma cell strain 3F9 capable of secreting a plasmodium CSP recombinant protein monoclonal antibody and application of the hybridoma cell strain 3F9. The hybridoma cell strain 3F9 is preserved in the China General Microbiological Culture Collection Center on August 21, 2024, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2024244; the monoclonal antibody secreted by the hybridoma cell strain 3F9 has good specificity on the plasmodium CSP protein, an ELISA detection method established by using the monoclonal antibody can be used for detecting the plasmodium CSP protein and has good specificity, the detection sensitivity is as low as 0.25 mu g / ml, and the monoclonal antibody has important significance on plasmodium CS P protein detection and plasmodium disease diagnosis.

The present invention relates to the technical field of drug application. Disclosed are patchouli alcohol, a patchouli alcohol compound antimalarial composition, and a use in preparation of an anti-plasmodial drug. The antimalarial pharmaceutical composition is a composition of artesunate and patchouli alcohol. By compounding patchouli alcohol and artesunate, synergistic antimalarial activity can be produced; and by reducing the plasmodium infection rate in red blood cells, patchouli alcohol and the compound antimalarial composition alleviate edema and inflammation in the liver and the spleen caused by malaria, and decrease haemozoin deposition in the liver and the spleen, having minimal toxic and side effects on the liver while exerting the antimalarial activity. The antimalarial effect of patchouli alcohol is obviously superior to that of patchouli oil, the antimalarial effect of the composition of artesunate and patchouli alcohol is obviously superior to that of artesunate or patchouli alcohol used alone, and patchouli alcohol and the composition of artesunate and patchouli alcohol especially have a more obvious inhibitory effect on artesunate-resistant plasmodium.

In one aspect, the disclosure relates to compounds that inhibit Plasmodium falciparum asexual blood stage parasites (PfABS) In one aspect, the compounds exhibit sub-millimolar potency against the intraerythrocytic stages of Plasmodium falciparum and other Plasmodium species. In another aspect, the compounds are soluble in aqueous solutions at pH 7.4, making them suitable for oral administration to patients. Also disclosed are methods of making the compounds, pharmaceutical compositions comprising the same, and methods of treating or preventing malaria using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.